NSE: GLENMARK · 6 October 2026
- Glenmark Pharmaceuticals shares moved up 0.70% on Tuesday, trading between an intraday high of ₹2318.00 and a low of ₹2277.30 before settling at ₹2311.00.
- Glenmark Therapeutics Inc., USA announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs to enhance consumer convenience and expand its U.S. dermatology portfolio. The product is comparable to the active ingredient of Differin Gel, which had annual sales of approximately $45.8 million for the 52-week period ending September 5, 2026, according to Nielsen syndicated data.
- Trading volume was 0.91 times the 20-day average daily volume.
Why is Glenmark Pharmaceuticals share price rising on 6 October 2026?
Glenmark Pharmaceuticals shares moved up 0.70% on Tuesday, trading between an intraday high of ₹2318.00 and a low of ₹2277.30 before settling at ₹2311.00.
The broader market and sectoral backdrop showed positive momentum, as the benchmark Nifty rose 0.98% while the Nifty Pharma sector index advanced 1.66%. Despite a negative return of 5.35% over the preceding five trading sessions, today's uptick aligns with broader sectoral strength.
Company disclosures showed that Glenmark Therapeutics Inc., USA announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs on October 6, 2026. While the launch expands its U.S. over-the-counter dermatology offerings, there is no direct evidence confirming it as the sole catalyst for today's price action.
4.92 lakh shares traded by 6 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 5.42 lakh shares (0.91 times). The five-day average daily volume was 8.00 lakh shares. Separately, the NSE report for 5 October 2026 showed 2.45 lakh shares delivered, representing 50.05% of that day’s traded volume. The same report recorded 43,734 trades.
The stock's 0.70% rise occurred alongside a positive move in the Nifty Pharma sector index, which gained 1.66%. Although the company announced a U.S. product launch on the same day, no direct causal link was established, making it a modest recovery supported by broader sectoral strength.
Latest Company Developments
Glenmark Therapeutics Inc., USA announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs to enhance consumer convenience and expand its U.S. dermatology portfolio. The product is comparable to the active ingredient of Differin Gel, which had annual sales of approximately $45.8 million for the 52-week period ending September 5, 2026, according to Nielsen syndicated data.
It strengthens the company's over-the-counter footprint in the U.S. dermatology market.
Glenmark Pharmaceuticals received the Establishment Inspection Report from the U.S. FDA for its formulations manufacturing facility located in Goa, India. The inspection, conducted from June 22 to June 30, 2026, classified the facility with a Voluntary Action Indicated status.
A VAI status resolves regulatory uncertainty for a key manufacturing site serving regulated markets.
Glenmark Specialty S.A. launched RYALTRIS Nasal Spray in Brazil for treating moderate to severe symptoms of allergic rhinitis in adults and adolescents. The introduction follows regulatory approval from ANVISA and brings the first olopatadine-containing intranasal combination therapy to the Brazilian market.
It broadens the global commercial footprint of Glenmark's flagship respiratory brand in key Latin American markets.
a press release dated October 06, 2026, titled "Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)".
a press release dated October 06, 2026, titled "Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.76% on 30 June 2026. This compares with 16.80% on 31 March 2026, a change of -0.04 percentage points.
The filing reported 37 MF/UTI holders.
Research & Brokerage Views
What to Watch Next
- Execution and sales trajectory of newly launched Adapalene Gel pump packs in the U.S. market
- Commercial uptake of Ryaltris following its recent launch in Brazil
- Cash volume and delivery percentage trends relative to the 20-day average volume
- Further regulatory updates from the U.S. FDA regarding manufacturing facilities
Other Dated Coverage
- Why Glenmark Shares Fell 1.54% Today: Sector Consolidation | 5 October 2026 — 5 October 2026
- Why Glenmark Shares Fell 4.37% Today: Sector Headwinds & Volume Analysis | 30 September 2026 — 30 September 2026
- Glenmark Pharma Shares Surge 4.98%: Why Glenmark Stock is Rising Today | 29 September 2026 — 29 September 2026
More Glenmark Pharmaceuticals news and dated analysis →
Frequently Asked Questions
What is the latest Glenmark Pharmaceuticals company news?
Glenmark Therapeutics Inc., USA announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs to enhance consumer convenience and expand its U.S. dermatology portfolio. The product is comparable to the active ingredient of Differin Gel, which had annual sales of approximately $45.8 million for the 52-week period ending September 5, 2026, according to Nielsen syndicated data.
How strong was Glenmark Pharmaceuticals’s trading volume?
4.92 lakh shares traded, 0.91 times the 20-day average daily volume. The price and volume data are dated 6 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Article by: WittyTrades Research Desk
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.